首页> 外国专利> METHOD OF PREVENTION OF INTRAPERITONEAL POSTOPERATIVE ADHESIONS

METHOD OF PREVENTION OF INTRAPERITONEAL POSTOPERATIVE ADHESIONS

机译:预防腹腔手术后粘连的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine, namely to surgery, and can be used to prevent the formation of intra-abdominal adhesions after undergoing operations on the abdominal organs. For this purpose perform a combined drug therapy. Within 2 days before the operation, Tivortin is administered every 12 hours, 50 ml intravenously at a rate of 20 drops per minute. In the intraoperative period, Parecoxib is administered at a dose of 120 mg intraperitoneally by irrigating the surgical field immediately before the completion of the surgical manual. In the early postoperative period: 2 hours after the operation, Parecoxib is administered at a dosage of 60 mg intravenously, followed by a 12-hour administration at a dosage of 30 mg intravenously for 3 days. In the postoperative period for 3 days, Tivortin is administered every 12 hours, 50 ml intravenously at a rate of 20 drops per minute. From the 4th postoperative day for 10 days, oral administration of Tivortin 1 g 3 times a day is carried out.;EFFECT: method reduces the likelihood of formation of intra-abdominal adhesions and the occurrence of adhesive disease after undergoing simultaneous operations, in particular, for cholelithiasis and ventral hernias, due to the pronounced anti-inflammatory effect and reduction of the process of fibrous-connective tissue changes caused by the simultaneous blocking of the synthesis of cyclooxygenase-2 and cytoprotection, membrane stabilization, which are achieved due to the introduction of these drugs at certain stages of treatment.;1 cl, 2 ex
机译:药物领域本发明涉及药物,即外科手术,可用于防止对腹部器官进行手术后腹腔内粘连的形成。为此,请进行联合药物治疗。手术前2天之内,每12小时静脉滴注Tivortin,每分钟20滴,每次50 ml。在术中,在完成手术手册之前,通过冲洗手术区域腹膜内给予帕瑞昔布,剂量为120 mg。在术后早期:手术后2小时,帕瑞昔布以60 mg静脉内给药,然后以12 mg 30 mg静脉内给药12小时,共3天。术后3天,每12小时静脉滴注Tivortin,每分钟20滴,剂量为50 ml。从术后第4天开始连续10天,每天3次口服Tivortin 1 g。;效果:该方法减少了腹腔内粘连的形成和发生粘连的可能性由于同时阻断环氧合酶2的合成和细胞保护膜引起的显着的抗炎作用和减少了纤维结缔组织变化的过程,因此在同时手术后尤其是胆石症和腹疝的治疗稳定,这是由于在某些治疗阶段引入了这些药物而实现的; 1 cl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号